Maintenance therapy is sometimes given after initial treatment has put lymphoma into remission (where lymphoma has been reduced or there is no evidence of lymphoma left in your body). It is used to keep under control any lymphoma cells that can’t be detected by scans but may be left in your body after the main treatment has finished. This aims to make the remission last as long as possible.
Antibody therapy is the most common type of maintenance therapy used for people with lymphoma.
Chemotherapy is sometimes used as maintenance therapy. Children and young people with lymphoblastic lymphoma may be given maintenance treatment with chemotherapy to prevent their lymphoma relapsing. This is a less intensive course of chemotherapy, usually given as an outpatient at regular intervals over a couple of years.
Maintenance therapy is given to people who go into remission after chemotherapy. Rituximab is an antibody therapy that is given as maintenance treatment to people with some types of advanced low-grade non-Hodgkin lymphoma. Maintenance rituximab is given once every 2 to 3 months.
- People with follicular lymphoma have maintenance for up to 2 years.
- Most people with mantle cell lymphoma have maintenance for a couple of years, but it can be shorter or longer than this depending on your individual circumstances and availability on the NHS.
There are clinical trials testing whether maintenance should continue for longer for everyone. Current evidence suggests there is no benefit to continuing maintenance beyond 2 years for most people with follicular lymphoma.
Other antibodies are also beginning to be used as maintenance treatments.
There are many targeted treatments for lymphoma that are being tested to see if using them as maintenance therapy reduces the risk of the lymphoma relapsing (coming back). Find out more about the importance of clinical trials in improving treatments and search for a trial that might be suitable for you at Lymphoma TrialsLink.
Having rituximab maintenance treatment for follicular lymphoma or mantle cell lymphoma can delay the need for more treatment. On average, remissions last significantly longer in people with these types of lymphoma who are given maintenance treatment than in people who do not have any maintenance.
There is currently not enough evidence of benefit for rituximab maintenance to be routinely used in other types of lymphoma.
Most people do not have troublesome side effects whilst on rituximab maintenance, but it isn’t suitable for everyone. Some people have bad reactions to rituximab. Other people have problems with side effects over time, such as infections. Your lymphoma specialist should discuss the risks and benefits of maintenance therapy with you if they recommend this treatment.